An aldose reductase inhibitor
Related Products
Labeled Version(s)
29993Epalrestat-d5
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Epalrestat

Item No. 15214

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5Z-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
CAS Number
82159-09-9
Synonyms
  • ONO-2235
Molecular Formula
C15H13NO3S2
Formula Weight
319.4
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 10 mg/mlDMF:PBS (pH 7.2) (1:1): 0.5 mg/mlDMSO: 2 mg/ml
λmax
237, 292, 390 nm
SMILES
CC(/C=C1SC(N(CC(O)=O)C\1=O)=S)=C\C2=CC=CC=C2
InChi Code
InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-
InChi Key
CHNUOJQWGUIOLD-NFZZJPOKSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $81

    Add

    10 mg

    $97

    Add

    25 mg

    $218

    Add

    50 mg

    $395

    Add
    Product Description

    Epalrestat is an inhibitor of aldose reductase (IC50s = 0.01 and 0.26 µM for rat lens and human placenta aldose reductase, respectively).1 It inhibits glucose-induced sorbitol accumulation in isolated rat lens, rat sciatic nerve, and human erythrocytes (IC50s = 1.5, 5, and 1.5 µM, respectively). It decreases high glucose-induced proliferation of vascular smooth muscle cells when used at a concentration of 10 nM and prevents high glucose-induced intracellular NADH/NAD+ increases and membrane-bound PKC activation at 100 nM.2,3 Epalrestat (20 and 40 mg/kg) improves motor nerve conduction velocity and decreases sorbitol content in the sciatic nerve and erythrocytes in a rat model of streptozotocin-induced diabetic neuropathy.4 It also prevents capillary strand formation in a rat model of diabetes-induced retinal microangiopathy when administered at a dose of 50 mg/kg.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Terashima, H., Hama, K., Yamamoto, R., et al. Effects of a new aldose reductase inhibitor on various tissues in vitro. J. Pharmacol. Exp. Ther. 229(1), 226-230 (1984).

    2. Yasunari, K., Kohno, M., Kano, H., et al. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose. Hypertension 35(5), 1092-1098 (2000).

    3. Yasunari, K., Kohno, M., Kano, H., et al. Aldose reductase inhibitor prevents hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cells induced by high glucose. Arterioscler. Thromb. Vasc. Biol. 15(12), 2207-2212 (1995).

    4. Kikkawa, R., Hatanaka, I., Yasuda, H., et al. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats. Diabetologia 24(4), 290-292 (1983).

    5. Kojima, K., Matsubara, H., Mizuno, K., et al. Experimentally induced diabetic retinal microangiopathy and polyol pathway. II. Effect of aldose reductase inhibitors on microangiopathy. Nippon Ganka Gakkai Zasshi 89(2), 247-256 (1985).